Beijing Konruns Pharmaceutical Co Ltd (603590) - Total Liabilities
Based on the latest financial reports, Beijing Konruns Pharmaceutical Co Ltd (603590) has total liabilities worth CN¥569.41 Million CNY (≈ $83.32 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beijing Konruns Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 603590 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Beijing Konruns Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Konruns Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yunnan Coal & Energy Co Ltd
SHG:600792
|
China | CN¥5.98 Billion |
|
Hello Group Inc
NASDAQ:MOMO
|
USA | $2.53 Billion |
|
Guangzhou KingTeller Technology Co Ltd
SHE:002177
|
China | CN¥25.84 Million |
|
Nanjing Canatal Data Centre Environmental Tech Co Ltd Class A
SHG:603912
|
China | CN¥2.11 Billion |
|
Pantoro Limited
F:RKN
|
Germany | €183.49 Million |
|
Latent View Analytics Limited
NSE:LATENTVIEW
|
India | Rs3.10 Billion |
|
Arvind Fashions Limited
NSE:ARVINDFASN
|
India | Rs30.55 Billion |
|
SLR Investment Corp
NASDAQ:SLRC
|
USA | $1.55 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Beijing Konruns Pharmaceutical Co Ltd (603590) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Konruns Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total liabilities of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥598.51 Million ≈ $87.58 Million |
+21.27% |
| 2024-12-31 | CN¥493.52 Million ≈ $72.22 Million |
+17.94% |
| 2023-12-31 | CN¥418.44 Million ≈ $61.23 Million |
+78.31% |
| 2022-12-31 | CN¥234.68 Million ≈ $34.34 Million |
-2.52% |
| 2021-12-31 | CN¥240.74 Million ≈ $35.23 Million |
-65.69% |
| 2020-12-31 | CN¥701.72 Million ≈ $102.68 Million |
+57.39% |
| 2019-12-31 | CN¥445.84 Million ≈ $65.24 Million |
+1.45% |
| 2018-12-31 | CN¥439.48 Million ≈ $64.31 Million |
+37.80% |
| 2017-12-31 | CN¥318.93 Million ≈ $46.67 Million |
+116.41% |
| 2016-12-31 | CN¥147.37 Million ≈ $21.56 Million |
-9.33% |
| 2015-12-31 | CN¥162.53 Million ≈ $23.78 Million |
-8.18% |
| 2014-12-31 | CN¥177.02 Million ≈ $25.90 Million |
-12.23% |
| 2013-12-31 | CN¥201.68 Million ≈ $29.51 Million |
-- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more